NASDAQ:ARVN - Arvinas Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $129.23
  • Forecasted Upside: 35.36 %
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 13 Buy Ratings
  • 0 Strong Buy Ratings
▲ +10.96 (12.97%)

This chart shows the closing price for ARVN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Arvinas Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARVN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARVN

Analyst Price Target is $129.23
▲ +35.36% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Arvinas in the last 3 months. The average price target is $129.23, with a high forecast of $170.00 and a low forecast of $93.00. The average price target represents a 35.36% upside from the last price of $95.47.

This chart shows the closing price for ARVN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 13 investment analysts is to buy stock in Arvinas. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/23/2021BMO Capital MarketsBoost Price TargetOutperform$101.00 ➝ $111.00High
7/23/2021CitigroupBoost Price TargetBuy$118.00 ➝ $153.00High
7/23/2021HC WainwrightReiterated RatingBuy$100.00 ➝ $135.00High
7/23/2021OppenheimerBoost Price TargetOutperform$100.00 ➝ $108.00High
7/22/2021Piper SandlerReiterated RatingOverweight$97.00 ➝ $105.00High
7/22/2021TruistBoost Price TargetBuy$150.00 ➝ $170.00High
7/22/2021Truist SecuritiesBoost Price TargetBuy$150.00 ➝ $170.00High
5/20/2021UBS GroupInitiated CoverageBuy$123.00High
4/21/2021Northern Trust Capital MarketsInitiated CoverageBuyLow
4/21/2021Truist SecuritiesInitiated CoverageBuy$150.00High
4/21/2021TruistInitiated CoverageBuy$150.00High
3/31/2021BMO Capital MarketsInitiated CoverageOutperform$101.00High
3/30/2021Cantor FitzgeraldBoost Price TargetOverweight$121.00 ➝ $140.00High
1/19/2021OppenheimerBoost Price Target$80.00 ➝ $100.00Low
1/5/2021Cantor FitzgeraldBoost Price TargetOverweight$66.00 ➝ $121.00N/A
12/21/2020Piper SandlerBoost Price TargetOverweight$58.00 ➝ $97.00Low
12/15/2020Smith Barney CitigroupBoost Price Target$43.00 ➝ $123.00High
12/15/2020Roth CapitalBoost Price TargetBuy$65.00 ➝ $120.00High
12/14/2020HC WainwrightReiterated RatingBuy$60.00 ➝ $100.00High
12/14/2020BMO Capital MarketsBoost Price TargetOutperform$62.00 ➝ $114.00High
12/14/2020OppenheimerUpgradeMarket Perform ➝ OutperformHigh
12/14/2020The Goldman Sachs GroupBoost Price TargetBuy$78.00 ➝ $129.00High
12/14/2020WedbushBoost Price TargetOutperform$62.00 ➝ $93.00High
12/1/2020Cantor FitzgeraldLower Price Target$75.00 ➝ $66.00Medium
10/9/2020Cantor FitzgeraldReiterated RatingOverweightHigh
10/8/2020OppenheimerReiterated RatingHoldHigh
8/4/2020OppenheimerInitiated CoverageHoldLow
6/1/2020CitigroupUpgradeNeutral ➝ Buy$45.00Medium
5/31/2020OppenheimerInitiated CoverageHoldLow
5/29/2020Cantor FitzgeraldReiterated RatingBuy$75.00Low
5/14/2020Cantor FitzgeraldReiterated RatingBuy$75.00Medium
5/11/2020OppenheimerInitiated CoverageMarket PerformMedium
5/4/2020Roth CapitalBoost Price TargetBuy$35.00 ➝ $65.00High
4/29/2020HC WainwrightReiterated RatingBuy$50.00 ➝ $60.00Medium
4/14/2020Cantor FitzgeraldReiterated RatingBuy$75.00Low
3/16/2020Piper SandlerReiterated RatingBuy$58.00High
1/30/2020BMO Capital MarketsReiterated RatingOutperform$62.00High
1/24/2020WedbushBoost Price TargetOutperform$39.00 ➝ $60.00Medium
1/6/2020Piper Jaffray CompaniesBoost Price TargetOverweight$35.00 ➝ $58.00N/A
12/20/2019Cantor FitzgeraldBoost Price TargetOverweight$42.00 ➝ $75.00Low
12/19/2019HC WainwrightInitiated CoverageBuy$50.00High
11/25/2019GuggenheimInitiated CoverageBuy$50.00High
11/14/2019Roth CapitalInitiated CoverageBuy$35.00Medium
11/13/2019Piper Jaffray CompaniesReiterated RatingBuy$32.00 ➝ $35.00High
10/24/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$23.00 ➝ $38.00Medium
9/24/2019WedbushInitiated CoverageOutperform$35.00 ➝ $38.00Low
9/12/2019BMO Capital MarketsInitiated CoverageOutperform$34.00High
8/5/2019Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$42.00 ➝ $42.00Medium
6/5/2019CitigroupDowngradeBuy ➝ Neutral$21.00 ➝ $22.00High
5/8/2019Piper Jaffray CompaniesBoost Price TargetOverweight$23.00 ➝ $32.00High
4/11/2019Evercore ISIInitiated CoverageOutperformHigh
10/22/2018CitigroupInitiated CoverageBuy ➝ Buy$21.00Low
10/22/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$17.00High
10/22/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$23.00High
(Data available from 7/24/2016 forward)
Arvinas logo
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.
Read More

Today's Range

Now: $95.47
Low: $85.57
High: $96.78

50 Day Range

MA: $75.83
Low: $63.79
High: $95.47

52 Week Range

Now: $95.47
Low: $19.68
High: $96.78


1,665,656 shs

Average Volume

466,353 shs

Market Capitalization

$4.68 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Arvinas?

The following Wall Street research analysts have issued reports on Arvinas in the last year: BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., HC Wainwright, Northern Trust Capital Markets, Oppenheimer Holdings Inc., Piper Sandler, Roth Capital, Smith Barney Citigroup, The Goldman Sachs Group, Inc., Truist, Truist Securities, UBS Group AG, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for ARVN.

What is the current price target for Arvinas?

13 Wall Street analysts have set twelve-month price targets for Arvinas in the last year. Their average twelve-month price target is $129.23, suggesting a possible upside of 35.4%. Truist has the highest price target set, predicting ARVN will reach $170.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $93.00 for Arvinas in the next year.
View the latest price targets for ARVN.

What is the current consensus analyst rating for Arvinas?

Arvinas currently has 13 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARVN will outperform the market and that investors should add to their positions of Arvinas.
View the latest ratings for ARVN.

What other companies compete with Arvinas?

How do I contact Arvinas' investor relations team?

Arvinas' physical mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company's listed phone number is (203) 535-1456 and its investor relations email address is [email protected] The official website for Arvinas is